Developer docs
API playgroundTry for free, no card

Search company profiles

Ripple Therapeutics

Full company profile

uuid000bbf9

Namestring
Ripple Therapeutics
Legal namestring
Ripple Therapeutics Corporation
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Ripple Therapeutics is a clinical-stage ophthalmic therapeutics company founded in January 2020 as a spinout from Interface Biologics and headquartered at the MaRS Discovery District in Toronto, Canada. The company is built around its proprietary Epidel® platform, a polymer-free prodrug engineering technology that chemically engineers drugs into controlled-release, fully degradable implants. These prodrugs undergo surface erosion to deliver zero-order (constant) drug release over 6-12 months, with dosage and duration engineerable per indication. The platform enables smaller implants deliverable via 30-gauge needles with approximately 10% of the drug loading of conventional sustained-release products, eliminating inflammatory polymer byproducts.

Ripple's lead clinical-stage asset is IBE-814 IVT, an intravitreal dexamethasone prodrug implant in Phase II (RIPPLE-1) development for diabetic macular edema (DME) and retinal vein occlusion (RVO). The pipeline includes RTC-620 (intracameral glaucoma implant partnered with AbbVie), RTC-1119 (latanoprost prodrug intracameral implant for glaucoma), and earlier-stage programs targeting Dry AMD/Geographic Atrophy, Wet AMD, post-cataract surgery inflammation, opioid use disorder, and central nervous system disorders.

The company operates a B2B licensing and co-development business model with no direct product sales. Revenue is generated through upfront payments, development and regulatory milestone payments, R&D project payments, and tiered royalties on net sales from partner-led commercialization. Strategic pharmaceutical partners include AbbVie, Glaukos, Bausch + Lomb, Théa Open Innovation, and Hovione. To date, Ripple has raised over $65M USD cumulatively, with approximately $15M in equity (Series A led by Théa Open Innovation in two tranches in 2020-2021), $21.8M from the AbbVie collaboration upfront, and additional non-dilutive partnership funding. Ripple leads preclinical development of partnered programs; partners assume clinical development and commercialization responsibility.

Short descriptiontext

Ripple Therapeutics is a clinical-stage ophthalmic therapeutics company developing the Epidel® polymer-free prodrug platform for sustained-release drug delivery implants. It partners with major pharmaceutical companies (AbbVie, Glaukos, Bausch + Lomb, Théa) to develop treatments for retinal and glaucoma diseases via licensing and co-development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic drug delivery, sustained release implants, prodrug therapeutics, biodegradable implants, ocular pharmaceuticals
Industry3 codes
PRIMARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic sustained drug delivery therapeutics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Agreements
TypeLicensing Royalties
Description

Licensing of Epidel technology platform to pharmaceutical partners for development of sustained release products. Includes upfront payments, clinical and regulatory milestone payments, and double-digit royalties on product sales.

rippletherapeutics.com
2Partnership Project Payments
TypeProfessional Services
Description

Non-dilutive funding from partnerships including project payments for development activities conducted on behalf of partners.

rippletherapeutics.com
3Milestone Payments
TypeLicensing Royalties
Description

Development and regulatory milestone payments tied to achievement of preclinical, clinical, and approval milestones under partnership agreements.

rippletherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ripple Therapeutics develops and licenses a proprietary polymer-free prodrug drug delivery platform (Epidel®) that chemically engineers active pharmaceutical ingredients into fully degradable, sustained-release implants targeting ophthalmic and other therapeutic areas. Its lead asset IBE-814 IVT is an intravitreal dexamethasone prodrug implant in Phase II for diabetic macular edema and retinal vein occlusion, while partnered programs include RTC-620 (glaucoma, with AbbVie) and RTC-1119 (glaucoma, with Glaukos). The company monetizes the platform through licensing agreements, upfront and milestone payments, and royalties on partner-commercialized products rather than direct sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 6-12 months sustained drug release with single injection vs monthly anti-VEGF injections
+3 more records
Product overview1 text field

Ripple Therapeutics is a clinical-stage biotech company built around a single proprietary platform — the Epidel® prodrug engineered sustained drug delivery platform — which chemically engineers drugs into standalone, fully degradable implants without polymers or excipients. The platform enables zero-order (constant) surface erosion-based drug release that is highly engineerable to tailor drug dose and duration per indication. The core commercial product is IBE-814 IVT, an intravitreal dexamethasone implant for DME and RVO (licensed to Théa Open Innovation), while the lead partnered pipeline programs include RTC-620 (glaucoma, partnered with AbbVie) and RTC-1119 (glaucoma intracameral implant, partnered with Glaukos). Additional pipeline products target Dry AMD/Geographic Atrophy, post-cataract surgery, Wet AMD, Opioid Use Disorder, and CNS disorders. The company operates a hybrid strategy combining proprietary products (via licensing to pharma partners) with platform co-development agreements (AbbVie, Glaukos, Bausch + Lomb, Hovione) that fund preclinical and clinical activities.

Product and service6 records
1Epidel® Platform
CategoryDrug delivery platform
Description

A patented prodrug engineering platform that chemically engineers active pharmaceutical ingredients into controlled-release pharmaceuticals without polymers or excipients. Proprietary prodrugs undergo surface erosion to enable zero-order, constant, sustained drug release that is highly engineerable to tailor drug dose and duration per indication; licensed to pharmaceutical partners for use with their APIs.

2IBE-814 IVT (Intravitreal Implant)
CategoryOphthalmic sustained-release implant
Description

A fully degradable intravitreal dexamethasone prodrug implant for treating diabetic macular edema (DME) and retinal vein occlusion (RVO). Delivers sustained low-dose dexamethasone for approximately 6 months via a 30-gauge needle injection, with approximately 1/10th the drug loading of commercial dexamethasone-releasing products; licensed to Théa Open Innovation for North America and Europe.

3RTC-620 Intracameral Implant
CategoryOphthalmic sustained-release implant
Description

A next-generation fully biodegradable, sustained-release intracameral implant with repeat dosing capabilities designed to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT); developed under collaboration with AbbVie with Ripple leading preclinical development.

4RTC-1119 Intracameral Implant
CategoryOphthalmic sustained-release implant
Description

A surface-eroding intracameral implant composed entirely of a latanoprost acid prodrug for long-term intraocular pressure control in glaucoma, targeting 6-12 months of controlled, predictable drug release with retreatability; currently in preclinical development.

5IBE-119 Intracameral Implant
CategoryOphthalmic sustained-release implant
Description

A prostaglandin-releasing intracameral implant for the treatment of primary open-angle glaucoma, based on the Epidel® platform technology.

6Dry AMD / Geographic Atrophy Program
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Evaluation program and licensing option agreement with affiliate of Bausch + Lomb Corporation. Bausch + Lomb funds early-stage feasibility and preclinical evaluation of target molecule with option to license formulations for additional consideration including milestones and royalties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-15
Description

Evaluation and licensing agreements enabling Glaukos to leverage Ripple's proprietary technology platform to create sustained release implants of targeted APIs for both glaucoma and retinal diseases. If program is successful, evaluation agreement automatically converts to licensing agreement with milestone payments and royalties.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Collaboration and option-to-license agreement to develop RTC-620, a next-generation fully biodegradable sustained release intracameral implant for glaucoma treatment. Ripple leads preclinical development; AbbVie leads clinical and commercialization upon option exercise. Ripple received $21.8M upfront and is eligible for up to $290M in milestones plus tiered royalties.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-12-15
Description

Exclusive licensing agreement for IBE-814 IVT in North America and Europe. Théa Open Innovation led Series A financing with $14.8M initial tranche. Théa will manage and finance Phase III pivotal trials. Deal includes upfront payment, clinical and regulatory milestones, and double-digit royalties.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

European ophthalmology specialty pharma and Ripple's licensing partner for IBE-814 IVT in North America/Europe. Comparable as a specialty ophthalmic pharma with sustained-release ophthalmic focus and partnership-driven pipeline expansion.

TypeDirect peer
Description

Clinical-stage company developing suprachoroidal injection-based drug delivery for retinal and choroidal diseases including macular edema and uveitis. Comparable as an ophthalmology-focused sustained/alternative delivery platform serving the same retinal specialist prescribers as Ripple's IBE-814 IVT.

TypeDirect peer
Description

Provider of surface modification and drug delivery coating technologies for medical devices, including ophthalmic implants. Overlapping surface-engineering and surface-erosion know-how that parallels Ripple's polymer-free prodrug drug release technology.

TypeDirect peer
Description

Specialty biopharma with a long-acting injectable/sustained-release technology focus and partnerships with large pharma for differentiated therapies. Comparable business model of leveraging proprietary delivery tech through partnership-licensed programs.

TypeRegional player
Description

Specialty ophthalmic pharma commercializing ILUVIEN, a long-acting intravitreal fluocinolone implant for chronic DME. Comparable sustained-release ophthalmic implant business model but commercially focused, providing a relevant benchmark for Ripple's commercial pathway.

TypeDirect peer
Description

Platform biotech commercializing ENHANZE, a subcutaneous drug delivery technology that enables long-acting injectable formulations via licensing deals with large pharma (Roche, Pfizer, Janssen, AbbVie). Highly comparable platform-licensing business model to Ripple's Epidel approach.

TypeDirect peer
Description

Developer of sustained-release ocular drug delivery products including YUTIQ (intravitreal fluocinolone insert for chronic DME/uveitis) and DEXYCU (intracameral dexamethasone). Most direct peer to Ripple's IBE-814 IVT given shared intravitreal, long-acting steroid implant mechanism for retinal diseases.

TypeDirect peer
Description

Clinical and commercial-stage sustained-release ophthalmic therapeutics company with approved DEXTENZA (intracanalicular dexamethasone insert). Directly comparable as it shares the small ocular sustained-release implant category targeting similar indications (post-surgical inflammation, retinal disease) with Ripple Therapeutics.

TypeBroad incumbent
Description

Established ophthalmic medical device and drug delivery company focused on MIGS and sustained-release glaucoma and retinal therapies (iDose TR, iLution). Both Ripple partner and a broader incumbent building a sustained-release franchise across the same indications Ripple targets.

TypeBroad incumbent
Description

Large biopharma with an approved ocular implant (Susvimo port delivery system with ranibizumab) for sustained anti-VEGF delivery in wet AMD. Defines the long-duration ocular implant category that Ripple's Epidel products compete against.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ripple Therapeutics

Ophthalmic sustained drug delivery therapeuticsrippletherapeutics.com

Ripple Therapeutics is a clinical-stage ophthalmic therapeutics company developing the Epidel® polymer-free prodrug platform for sustained-release drug delivery implants. It partners with major pharmaceutical companies (AbbVie, Glaukos, Bausch + Lomb, Théa) to develop treatments for retinal and glaucoma diseases via licensing and co-development.

What Ripple Therapeutics does

Ripple Therapeutics is a clinical-stage ophthalmic therapeutics company founded in January 2020 as a spinout from Interface Biologics and headquartered at the MaRS Discovery District in Toronto, Canada. The company is built around its proprietary Epidel® platform, a polymer-free prodrug engineering technology that chemically engineers drugs into controlled-release, fully degradable implants. These prodrugs undergo surface erosion to deliver zero-order (constant) drug release over 6-12 months, with dosage and duration engineerable per indication. The platform enables smaller implants deliverable via 30-gauge needles with approximately 10% of the drug loading of conventional sustained-release products, eliminating inflammatory polymer byproducts.

Ripple's lead clinical-stage asset is IBE-814 IVT, an intravitreal dexamethasone prodrug implant in Phase II (RIPPLE-1) development for diabetic macular edema (DME) and retinal vein occlusion (RVO). The pipeline includes RTC-620 (intracameral glaucoma implant partnered with AbbVie), RTC-1119 (latanoprost prodrug intracameral implant for glaucoma), and earlier-stage programs targeting Dry AMD/Geographic Atrophy, Wet AMD, post-cataract surgery inflammation, opioid use disorder, and central nervous system disorders.

The company operates a B2B licensing and co-development business model with no direct product sales. Revenue is generated through upfront payments, development and regulatory milestone payments, R&D project payments, and tiered royalties on net sales from partner-led commercialization. Strategic pharmaceutical partners include AbbVie, Glaukos, Bausch + Lomb, Théa Open Innovation, and Hovione. To date, Ripple has raised over $65M USD cumulatively, with approximately $15M in equity (Series A led by Théa Open Innovation in two tranches in 2020-2021), $21.8M from the AbbVie collaboration upfront, and additional non-dilutive partnership funding. Ripple leads preclinical development of partnered programs; partners assume clinical development and commercialization responsibility.

Ripple Therapeutics firmographics

Firmographics
Name
Ripple Therapeutics
Legal name
Ripple Therapeutics Corporation
Website
https://rippletherapeutics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Ripple Therapeutics is a clinical-stage ophthalmic therapeutics company developing the Epidel® polymer-free prodrug platform for sustained-release drug delivery implants. It partners with major pharmaceutical companies (AbbVie, Glaukos, Bausch + Lomb, Théa) to develop treatments for retinal and glaucoma diseases via licensing and co-development.
Ownership category
akta.pro rank

Ripple Therapeutics industry classification

Industry
Product category
Ophthalmic sustained drug delivery therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Ophthalmic drug delivery
  • Sustained release implants
  • Prodrug therapeutics
  • Biodegradable implants
  • Ocular pharmaceuticals

Where Ripple Therapeutics is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Ripple Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing Agreements: Licensing of Epidel technology platform to pharmaceutical partners for development of sustained release products. Includes upfront payments, clinical and regulatory milestone payments, and double-digit royalties on product sales.
  2. Partnership Project Payments: Non-dilutive funding from partnerships including project payments for development activities conducted on behalf of partners.
  3. Milestone Payments: Development and regulatory milestone payments tied to achievement of preclinical, clinical, and approval milestones under partnership agreements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Ripple Therapeutics product offering

Product offering

Core offering

Ripple Therapeutics develops and licenses a proprietary polymer-free prodrug drug delivery platform (Epidel®) that chemically engineers active pharmaceutical ingredients into fully degradable, sustained-release implants targeting ophthalmic and other therapeutic areas. Its lead asset IBE-814 IVT is an intravitreal dexamethasone prodrug implant in Phase II for diabetic macular edema and retinal vein occlusion, while partnered programs include RTC-620 (glaucoma, with AbbVie) and RTC-1119 (glaucoma, with Glaukos). The company monetizes the platform through licensing agreements, upfront and milestone payments, and royalties on partner-commercialized products rather than direct sales.

Product overview

Ripple Therapeutics is a clinical-stage biotech company built around a single proprietary platform — the Epidel® prodrug engineered sustained drug delivery platform — which chemically engineers drugs into standalone, fully degradable implants without polymers or excipients. The platform enables zero-order (constant) surface erosion-based drug release that is highly engineerable to tailor drug dose and duration per indication. The core commercial product is IBE-814 IVT, an intravitreal dexamethasone implant for DME and RVO (licensed to Théa Open Innovation), while the lead partnered pipeline programs include RTC-620 (glaucoma, partnered with AbbVie) and RTC-1119 (glaucoma intracameral implant, partnered with Glaukos). Additional pipeline products target Dry AMD/Geographic Atrophy, post-cataract surgery, Wet AMD, Opioid Use Disorder, and CNS disorders. The company operates a hybrid strategy combining proprietary products (via licensing to pharma partners) with platform co-development agreements (AbbVie, Glaukos, Bausch + Lomb, Hovione) that fund preclinical and clinical activities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Epidel® Platform A patented prodrug engineering platform that chemically engineers active pharmaceutical ingredients into controlled-release pharmaceuticals without polymers or excipients. Proprietary prodrugs undergo surface erosion to enable zero-order, constant, sustained drug release that is highly engineerable to tailor drug dose and duration per indication; licensed to pharmaceutical partners for use with their APIs.
  • IBE-814 IVT (Intravitreal Implant) A fully degradable intravitreal dexamethasone prodrug implant for treating diabetic macular edema (DME) and retinal vein occlusion (RVO). Delivers sustained low-dose dexamethasone for approximately 6 months via a 30-gauge needle injection, with approximately 1/10th the drug loading of commercial dexamethasone-releasing products; licensed to Théa Open Innovation for North America and Europe.
  • RTC-620 Intracameral Implant A next-generation fully biodegradable, sustained-release intracameral implant with repeat dosing capabilities designed to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT); developed under collaboration with AbbVie with Ripple leading preclinical development.
  • RTC-1119 Intracameral Implant A surface-eroding intracameral implant composed entirely of a latanoprost acid prodrug for long-term intraocular pressure control in glaucoma, targeting 6-12 months of controlled, predictable drug release with retreatability; currently in preclinical development.
  • IBE-119 Intracameral Implant A prostaglandin-releasing intracameral implant for the treatment of primary open-angle glaucoma, based on the Epidel® platform technology.
  • Dry AMD / Geographic Atrophy Program

Quantifiable outcome

  • 6-12 months sustained drug release with single injection vs monthly anti-VEGF injections
  • +3 more outcomes

Companies that use Ripple Therapeutics

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Ripple Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ripple Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • Bausch + LombcoreStrategic or Co-development Partner · 25 November 2025Evaluation program and licensing option agreement with affiliate of Bausch + Lomb Corporation. Bausch + Lomb funds early-stage feasibility and preclinical evaluation of target molecule with option to license formulations for additional consideration including milestones and royalties.
  • Glaukos CorporationcoreStrategic or Co-development Partner · 15 October 2024Evaluation and licensing agreements enabling Glaukos to leverage Ripple's proprietary technology platform to create sustained release implants of targeted APIs for both glaucoma and retinal diseases. If program is successful, evaluation agreement automatically converts to licensing agreement with milestone payments and royalties.
  • AbbVieflagshipStrategic or Co-development Partner · 17 September 2024Collaboration and option-to-license agreement to develop RTC-620, a next-generation fully biodegradable sustained release intracameral implant for glaucoma treatment. Ripple leads preclinical development; AbbVie leads clinical and commercialization upon option exercise. Ripple received $21.8M upfront and is eligible for up to $290M in milestones plus tiered royalties.
  • Théa Open Innovation (Laboratoires Théa)flagshipStrategic or Co-development Partner · 15 December 2020Exclusive licensing agreement for IBE-814 IVT in North America and Europe. Théa Open Innovation led Series A financing with $14.8M initial tranche. Théa will manage and finance Phase III pivotal trials. Deal includes upfront payment, clinical and regulatory milestones, and double-digit royalties.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Ripple Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Laboratoires Théa (Théa Open Innovation): European ophthalmology specialty pharma and Ripple's licensing partner for IBE-814 IVT in North America/Europe. Comparable as a specialty ophthalmic pharma with sustained-release ophthalmic focus and partnership-driven pipeline expansion.
  • Glaukos Corporation: Established ophthalmic medical device and drug delivery company focused on MIGS and sustained-release glaucoma and retinal therapies (iDose TR, iLution). Both Ripple partner and a broader incumbent building a sustained-release franchise across the same indications Ripple targets.
  • Genentech / Roche (Susvimo / Port Delivery System): Large biopharma with an approved ocular implant (Susvimo port delivery system with ranibizumab) for sustained anti-VEGF delivery in wet AMD. Defines the long-duration ocular implant category that Ripple's Epidel products compete against.

Direct peers

  • Clearside Biomedical: Clinical-stage company developing suprachoroidal injection-based drug delivery for retinal and choroidal diseases including macular edema and uveitis. Comparable as an ophthalmology-focused sustained/alternative delivery platform serving the same retinal specialist prescribers as Ripple's IBE-814 IVT.
  • Surmodics: Provider of surface modification and drug delivery coating technologies for medical devices, including ophthalmic implants. Overlapping surface-engineering and surface-erosion know-how that parallels Ripple's polymer-free prodrug drug release technology.
  • Theravance Biopharma: Specialty biopharma with a long-acting injectable/sustained-release technology focus and partnerships with large pharma for differentiated therapies. Comparable business model of leveraging proprietary delivery tech through partnership-licensed programs.
  • Halozyme Therapeutics: Platform biotech commercializing ENHANZE, a subcutaneous drug delivery technology that enables long-acting injectable formulations via licensing deals with large pharma (Roche, Pfizer, Janssen, AbbVie). Highly comparable platform-licensing business model to Ripple's Epidel approach.
  • EyePoint Pharmaceuticals: Developer of sustained-release ocular drug delivery products including YUTIQ (intravitreal fluocinolone insert for chronic DME/uveitis) and DEXYCU (intracameral dexamethasone). Most direct peer to Ripple's IBE-814 IVT given shared intravitreal, long-acting steroid implant mechanism for retinal diseases.
  • Ocular Therapeutix: Clinical and commercial-stage sustained-release ophthalmic therapeutics company with approved DEXTENZA (intracanalicular dexamethasone insert). Directly comparable as it shares the small ocular sustained-release implant category targeting similar indications (post-surgical inflammation, retinal disease) with Ripple Therapeutics.

Regional players

  • Alimera Sciences: Specialty ophthalmic pharma commercializing ILUVIEN, a long-acting intravitreal fluocinolone implant for chronic DME. Comparable sustained-release ophthalmic implant business model but commercially focused, providing a relevant benchmark for Ripple's commercial pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Ripple Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ripple Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Ripple Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ripple Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ripple Therapeutics

What does Ripple Therapeutics do?

Ripple Therapeutics develops and licenses a proprietary polymer-free prodrug drug delivery platform (Epidel®) that chemically engineers active pharmaceutical ingredients into fully degradable, sustained-release implants targeting ophthalmic and other therapeutic areas. Its lead asset IBE-814 IVT is an intravitreal dexamethasone prodrug implant in Phase II for diabetic macular edema and retinal vein occlusion, while partnered programs include RTC-620 (glaucoma, with AbbVie) and RTC-1119 (glaucoma, with Glaukos). The company monetizes the platform through licensing agreements, upfront and milestone payments, and royalties on partner-commercialized products rather than direct sales.

Is Ripple Therapeutics a public or private company?

Ripple Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ripple Therapeutics founded?

Ripple Therapeutics was founded in 2020. It employs 11 to 50 people.

Where is Ripple Therapeutics based?

Ripple Therapeutics is headquartered in Toronto, Canada, in the North America region.

How does Ripple Therapeutics make money?

Three revenue lines are on record. Licensing Agreements are the primary driver. The others are partnership Project Payments and milestone Payments.

Who are Ripple Therapeutics's main competitors?

Broad incumbents on record are Laboratoires Théa (Théa Open Innovation), Glaukos Corporation and Genentech / Roche (Susvimo / Port Delivery System). Direct peers are Clearside Biomedical, Surmodics, Theravance Biopharma, Halozyme Therapeutics, EyePoint Pharmaceuticals and Ocular Therapeutix. Alimera Sciences is listed as a regional player.

Does Ripple Therapeutics have an API?

No public API is recorded for Ripple Therapeutics.

What industry is Ripple Therapeutics in?

Ripple Therapeutics's product category is Ophthalmic sustained drug delivery therapeutics. Its primary akta.pro industry code is HLAHAIAJ, Nebulizers & Aerosol Drug Delivery Systems, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MedCity NewsGlaucoma Drug Fails Trial, But Bausch + Lomb Sees Opportunity in Another Eye DiseaseBausch + Lomb's experimental drug BL1107 failed to meet the primary goal of its Phase 2 glaucoma trial, though it did achieve a secondary endpoint of reducing intraocular eye pressure. The drug, acquired from Whitecap Biosciences in 2025 for $28 million upfront, was primarily acquired for its potential in treating geographic atrophy, an advanced form of dry age-related macular degeneration. The company plans to test BL1107 in a new clinical trial for geographic atrophy using a sustained-release implant in collaboration with Ripple Therapeutics, with trials expected to begin in 2028.FierceBiotechBausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 failBausch + Lomb has abandoned development of its BL1107 eye drop candidate after it failed a Phase 2 clinical trial for glaucoma, missing the primary endpoint of improving visual sensitivity in 159 patients with primary open-angle glaucoma or ocular hypertension. The setback is significant as BL1107 was acquired from Whitecap Biosciences for $28 million last year and was considered the company's next major hope in the glaucoma space. Moving forward, Bausch + Lomb will shift focus to developing a sustained-release implant version (WB006) for geographic atrophy, with clinical trials planned for 2028 in collaboration with Ripple Therapeutics.pharmaphorumBausch + Lomb drug fails in glaucoma, but a new use beckonsBausch + Lomb abandoned its glaucoma drug BL1107 after a phase 2 trial failed to show visual improvement. The company will now pursue a sustained-release implant for geographic atrophy, with trials planned for 2028. It cites a $1 billion-plus market for the new indication.BioSpaceBausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective CandidateBausch + Lomb announced Phase 2 results for BL1107 in glaucoma, which did not meet its primary endpoint. The company will discontinue the topical eye drop program but continue pursuing a sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.Business Wire BlogBausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective CandidateBausch + Lomb announced that its Phase 2 study evaluating BL1107 for glaucoma did not meet its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study, leading the company to discontinue development of the topical eye drop for this indication. Based on these results, the company will shift focus entirely to developing a sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028. The company acquired Whitecap Biosciences in 2025 primarily for the sustained-release implant technology and continues to collaborate with Ripple Therapeutics on the candidate.Eyes On EyecareBausch + Lomb and Ripple Therapeutics partner to develop sustained-release implantsBausch + Lomb and Ripple Therapeutics are partnering to develop sustained-release implants for ophthalmic diseases, with B+L funding early-stage feasibility and preclinical evaluation. The agreement includes an option to license formulations for additional milestones and royalties, though no target disease was disclosed.PharmiWeb.comRipple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma ManagementRipple Therapeutics and AbbVie announced a collaboration to develop RTC-620, a biodegradable sustained-release implant for glaucoma. Ripple will lead preclinical development, with AbbVie leading clinical and commercialization upon option exercise. The deal includes a $21.8 million upfront payment and up to $290 million in option fees and milestones.YahooRipple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma ManagementRipple Therapeutics and AbbVie announced a collaboration to develop RTC-620, a biodegradable sustained-release implant for glaucoma. Ripple leads preclinical development; AbbVie leads clinical and commercialization upon option exercise. Ripple receives $21.8M upfront and up to $290M in option fees and milestones.VentureRadarTop polymer engineering start-upsThe article presents a curated list of top polymer engineering start-ups founded since 2020, highlighting companies such as Graphyte, Ripple Therapeutics, and Constructive Bio. It provides brief descriptions of their technologies, including carbon removal, implantable prodrugs, and genome rewriting, along with their founding year and country of origin. The content serves as an index or directory entry rather than reporting on specific corporate events or developments.